Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA

NCT: NCT04816591 · COMPLETED

NCT IDNCT04816591
StatusCOMPLETED
Start Date2021-05-27
Completion2025-03-26

Brief Summary

This is a prospective, multi-center, open-label, randomized controlled study in which subjects can receive standard of care (SOC) alone or SOC and TRUFILL n-BCA MMA embolization for the treatment of chronic subdural hematomas (cSDH).

Frequently Asked Questions

What is Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA?

Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA is a clinical trial registered under NCT04816591. Current status: COMPLETED.

What is the status of NCT04816591?

The current status of NCT04816591 (Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA) is: COMPLETED.

When did Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA start?

Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA started on 2021-05-27.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑